Prof. Arthur Sagalowsky: cytoreductive nephrectomy is still important for advanced/metastatic renal cell cancer but many still need to be proved

Posted On 2016-10-24 10:14:30

Urology and Surgery. He is the holder of the Paul C. Peters Chair in Urology in Memory of Rumsey and Louis Strickland.Prof. Sagalowsky specializes in all aspects of urological malignancies and related urinary tract reconstruction. He has unique surgical experience with: radical cystectomy and continent urinary diversion with orthotopic neobladders and cutaneous reservoirs; open nerve-sparing radical prostatectomy, and, in select cases, nerve-sparing cystoprostatectomy for patients with prostate cancer or bladder cancer; complex partial nephrectomy for patients with large localized kidney tumors where preservation of renal function by nephron sparing surgery is important; radical nephrectomy for large kidney tumor debulking; and resection of tumors with tumor thrombus into the vena cava (and even into the heart); debulking retroperitoneal lymph node dissection for testis cancer.

His research interests involve translational studies on bladder cancer and kidney cancer involving clinical diagnosis and treatment, and translational studies on molecular pathways as predictors of disease behavior and risk for recurrence, progression, response to treatment and disease-related mortality. He has published and spoken widely on these topics and has extensive experience in clinical trials.

Prof. Sagalowsky is a member of the American Association for Cancer Research, American College of Surgeons, American Society of Transplant Surgeons, American Urological Association, the Society of Urologic Oncology, and the American Association of Genitourinary Surgeons. He has been honored by Texas Monthly as a Super Doctor, and he is listed in America’s Top Doctors for Cancer.


The Editor with Prof. Arthur Sagalowsky